3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Phase 1/2
1
Phase 1
1
Status
Completed
4
Sponsor Class
INDUSTRY
4
Study Type
Interventional
4
Sponsor
Cancer Type
Thoracic
35
Gastrointestinal
31
Genitourinary
20
Gynecologic
16
Head & Neck
13
Dermatologic
10
Breast
9
Lymphoid
4
Other solid neoplasm
3
Endocrine
2
Sarcoma
1
NET
1
CNS
1
Conditions
Lymphoma
551
Precursor Cell Lymphoblastic Leukemia-Lymphoma
511
Lymphoma, Non-Hodgkin
439
Lymphoma, Follicular
407
Lymphoma, Large B-Cell, Diffuse
392
Leukemia, Lymphocytic, Chronic, B-Cell
392
Lymphoma, B-Cell
249
Lymphoma, Mantle-Cell
224
Hodgkin Disease
209
Recurrence
206
Leukemia, Myeloid, Acute
199
Leukemia
197
Multiple Myeloma
186
Burkitt Lymphoma
185
Lymphoma, B-Cell, Marginal Zone
170
Neoplasms
153
Myelodysplastic Syndromes
134
Hematologic Neoplasms
115
Waldenstrom Macroglobulinemia
103
Lymphoma, T-Cell, Peripheral
86
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
83
Lymphoma, T-Cell
82
Lymphoma, T-Cell, Cutaneous
67
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
63
Mycosis Fungoides
57
Leukemia, Biphenotypic, Acute
55
Breast Neoplasms
55
Leukemia, B-Cell
52
Myeloproliferative Disorders
50
Lymphoproliferative Disorders
47
Interventions
pembrolizumab
4
Gemcitabine
1
Brentuximab Vedotin
1
Bendamustine Hydrochloride
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
4 trials
Recent
Start date
Enrollment
Parkinson Disease 4, Autosomal Dominant Lewy Body
×
Lymphoid
×
1 year
×
Clear all
NCT02684292
2026-02-18
MK-3475-204
Merck Sharp & Dohme LLC
Phase 3
Completed
304 enrolled
1 FDA
NCT03598608
2026-02-05
MK-4280-003
Merck Sharp & Dohme LLC
Phase 1/2
Completed
137 enrolled
NCT05508867
2026-01-20
MK-4280A-008
Merck Sharp & Dohme LLC
Phase 2
Completed
203 enrolled
NCT03010176
2025-10-29
MK-1454-001
Merck Sharp & Dohme LLC
Phase 1
Completed
156 enrolled
20 charts